Figure 5.

Outcomes of CEBPA-mutant patients according to co-occurring CSF3R and GATA2 mutational status. (A) EFS of dual CEBPA⁺/CSF3R⁺ mutant patients compared to those with dual CEBPA⁺/GATA2⁺ and those with a CEBPA⁺ mutation and neither CSF3R nor GATA2; (B) RR of dual CEBPA⁺/CSF3R⁺ mutant patients compared to dual CEBPA⁺/GATA2⁺ and patients with a CEBPA⁺ mutation and neither CSF3R nor GATA2; (C) OS of dual CEBPA⁺/CSF3R⁺ mutant patients compared to dual CEBPA⁺/GATA2⁺ and patients with a CEBPA⁺ mutation and neither CSF3R nor GATA2.